Arsenic trioxide and all- trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial
Burnett, Alan K, Prof, Russell, Nigel H, Prof, Hills, Robert K, DPhil, Bowen, David, Prof, Kell, Jonathan, MD, Knapper, Steve, DM, Morgan, Yvonne G, PhD, Lok, Jennie, MSc, Grech, Angela, BA, Jones, Gail, MD, Khwaja, Asim, Prof, Friis, Lone, PhD, McMullin, Mary Frances, Prof, Hunter, Ann, MD, Clark, Richard E, Prof, Grimwade, David, Prof
Published in The lancet oncology (01.10.2015)
Published in The lancet oncology (01.10.2015)
Get full text
Journal Article
De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial
Clark, Richard E, Polydoros, Fotios, Apperley, Jane F, Milojkovic, Dragana, Pocock, Christopher, Smith, Graeme, Byrne, Jenny L, de Lavallade, Hugues, O'Brien, Stephen G, Coffey, Tony, Foroni, Letizia, Copland, Mhairi
Published in The Lancet. Haematology (01.07.2017)
Published in The Lancet. Haematology (01.07.2017)
Get more information
Journal Article